Stock Analiz

InflaRx N.V. IFRX

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$1.17Market cap $172M
Open the interactive analysis →

InflaRx N.V. (IFRX) is a healthcare company listed in the US with a market value of about $172M. In fiscal year 2025 it had revenue of $34464 and net income of -$54M, a net margin of -155582.1%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -677%.

About InflaRx

InflaRx is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5,003.0
P/B20.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-24.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-80.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-62731.1%
ROIC (5-yr avg.)-676.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$34464$172238$69713-$34M———-$43M-$23M-$7M
Net income-$54M-$48M-$47M-$31M-$52M-$42M-$60M-$34M-$29M-$9M
Free cash flow-$42M-$50M-$42M-$36M-$45M-$45M————
EPS (diluted)$-0.36$-0.32$-0.32$-0.21$-0.35$-0.28$-0.41$-0.23$-0.20$-0.06
Net margin-155600.0%-27785.0%-67630.7%91.5%———79.5%124.6%129.7%
ROIC-502.5%-489.0%-480.6%-350.9%-1561.7%—————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does InflaRx pay a dividend?

Not currently.

Is InflaRx a good stock to buy?

We do not give buy or sell advice. InflaRx scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.